New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis

BACKGROUND: Health Canada posts the outcomes of all New Drug Submissions. In some cases, companies have withdrawn submissions or submissions have been rejected by Health Canada for new active substances (NAS). This study explores the reasons for those decisions and compares them with decisions made...

Descripción completa

Detalles Bibliográficos
Autor principal: Lexchin, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270583/
https://www.ncbi.nlm.nih.gov/pubmed/37319240
http://dx.doi.org/10.1371/journal.pone.0286802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270583/
https://www.ncbi.nlm.nih.gov/pubmed/37319240
http://dx.doi.org/10.1371/journal.pone.0286802

Ejemplares similares